Caroline Palomeque
Stock Analyst at Maxim Group
(1.24)
# 3,760
Out of 5,138 analysts
10
Total ratings
44.44%
Success rate
-1.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $1.93 | +314.51% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $36.22 | +62.89% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $285.04 | -45.97% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $71.21 | -18.55% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $205.83 | -19.35% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $17.99 | +116.79% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $13.62 | +347.87% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $5.01 | +698.40% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $1.93
Upside: +314.51%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $36.22
Upside: +62.89%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $285.04
Upside: -45.97%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $71.21
Upside: -18.55%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $205.83
Upside: -19.35%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $17.99
Upside: +116.79%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $13.62
Upside: +347.87%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $5.01
Upside: +698.40%